Skip to content

+1 877 566 4981

info@fdamap.com

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • NDA Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us
Contact Us
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • NDA Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us

Day: February 3, 2022

Virtual Patient-Doctor Interactions for Care and Clinical Trials Should Stay

April 28, 2025February 3, 2022 by Prahsant Kumar

Remote care has arrived, thanks for the pandemic. For clinical trials also virtual or remote trials have become a necessity with all trials switching to remote trial management and operations to an extent unfathomable just two years ago. So, why do we even need to go back to the old 2019 methods? Perhaps this is … Read more

Categories Blog

Mark Cuban Tests If A Compounding Pharmacy Can be a Generic Manufacturer 

April 28, 2025February 3, 2022 by Prahsant Kumar

Compounding essential drugs at low cost is not a new idea but branding them as generic drugs is risky. Celebrity billionaire Mark Cuban announced a new generic drugs company that pledges to manufacture and sell prescription generic drugs at lower costs however the company will initially start a compounding pharmacy and then later convert to … Read more

Categories Blog

Recent Posts

  • FDA’s Transition to a Unified Adverse Event Framework
  • De-risking Drug Development with Fit-for-Purpose Non-Animal Models
  • Navigating the New Regulatory Framework for Biosimilars: FDA Slashes PK Hurdles and Streamlines the Biosimilar Pipeline
  • Strategic Response Management: Aligning 483 Remediation
  • Unlocking the FDA’s 3-Year Exclusivity: What Drug Developers Need to Know

Recent Comments

No comments to show.

One-stop source for FDA consultation, regulatory affairs training, and clinical trial services.

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin

Services

  • Webinars
  • Workshops
  • On-Demand Webinars
  • Custom training
  • Training Subscriptions

Company

  • About Us
  • Our Client
  • Testimonials
  • Free Resources
  • Newsletter

Support

  • Contact Us
  • Terms of Service
  • Privacy Policy

Payment Method

100% Secure Transaction

Copyright © 2025 FDAMap.com. All rights reserved.